Director, Digitized Case Processing & Digital Adverse Event Interfaces

Working with Us

Challenging. Meaningful. Life‑changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it.

You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high‑achieving teams. Take your career farther than you thought possible.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more

We’re looking for a Director of Digitized Case Processing & Digital Adverse Event Interfaces – a leader who sits comfortably at the crossroads of pharmacovigilance science, cutting‑edge technology, global regulation, and people leadership.

You’re probably already senior in your PV career. You’ve led teams, managed vendors, survived inspections, and built interfaces that actually work. But you’re restless. You’ve seen how much of PV case intake is still manual, slow, and fragile and you’ve been thinking about how to change it. You’ve got opinions about AI in GxP environments, about touchless processing, and about how literature screening should be done in 2026 and beyond.

That’s the weight and the privilege of this role. And if that excites rather than intimidates you, read on.

• Leading the AI‑powered transformation of adverse event intake:
  You’ll define and own BMS’s multi‑year digital intake roadmap, deploying AI/NLP, OCR, RPA, LLMs, and Agentic AI to build genuinely automated, touchless AE case creation workflows, all within a validated GxP framework. You’ll have your name on a transformation that most PV professionals only read about in conference presentations.
• Owning the interfaces that connect BMS’s safety ecosystem:
  From Medical Information and Clinical Development teams to CROs, licensing partners, and regulatory portals like FAERS, Eudra Vigilance, MHRA, and PMDA, you’ll own every channel through which adverse event data flows in and out of BMS. You’ll drive ICH E2B(R3) electronic exchange adoption and replace manual transmissions with validated, auditable data pipelines.
• Reinventing how BMS screens medical literature:
  You’ll lead the digital transformation of BMS’s Medical Literature Screening programme moving to AI/NLP‑driven screening across global databases including Pub Med, EMBASE, Cochrane, and J‑Stage. You’ll govern search string development, manage AI classifier calibration, and ensure the programme is always audit‑ready.
• Building and leading a world‑class global team:
  You’ll lead a geographically distributed team across the US, UK, Switzerland, India, and Japan, building a culture of psychological safety, scientific rigour, and continuous improvement. You’ll define career pathways, upskill your team in AI/ML fundamentals, and develop the next generation of PV innovation leaders.
• Turning data into decisions:
  You’ll design and own the KPI framework for your function, touchless processing rates, intake cycle times, data completeness, literature screening accuracy, and vendor SLA performance. You’ll use operational analytics and AI‑generated dashboards to identify bottlenecks and continuously raise the bar.

You’ll need 10+ years in Pharmacovigilance or Drug Safety, including at least 3–5 years at Director level, and a minimum of 7 years of hands‑on experience in ICSR data acquisition, case intake, or processing in pharma, biotech, or CRO environments.

What truly sets you apart is your ability to take a digital transformation vision and make it real — translating ambiguous future‑state thinking into clear, actionable roadmaps that get delivered. You’re equally at home in a regulatory conversation about ICH E2B(R3) compliance…